 Wave Life Sciences Ltd NASDAQ: WVE presented new preclinical data for its ADAR-mediated RNA editing capability ADAR editing and an update on its discovery-stage alpha-1 antitrypsin deficiency AATD program. Related Link: Wave Life Sciences RNA Editing Platform Shows Restoration of Functional AAT Protein in Preclinical Study 